Skip to main content
. Author manuscript; available in PMC: 2010 Feb 20.
Published in final edited form as: Semin Radiat Oncol. 2008 Jan;18(1):67–72. doi: 10.1016/j.semradonc.2007.10.001

Table 1.

Domains evaluated by instruments that have been validated to measure HRQOL effects of primary, definitive treatment for early stage prostate cancer.

HRQOL
Instrument 		Evaluated HRQOL Domains
Function
vs Bother		 Urinary
Incontinence		 Urinary
Irritation		 Bowel /
Rectal		 Sexual Vitality/
Hormonal
UCLA-PCI X X X X
EORTC-QLQ30
Prostate Module		 X X1 X1 X X
EPIC-50 X X X X X X
Symptom Index X X X X X
EPIC-262 X2 X X X X X
1

Urinary assessment in the EORTC Prostate module includes items about incontinence and irritation/obstruction but subscale scores are not used to discern these 2 domains, instead only a urinary summary score is provided.

2

Bother items that comprise the UCLA-PCI bother subscales are retained as part of EPIC-26, enabling calculation of bother scores for overall urinary bother that can be measured distinctly from urinary incontinence or irritative/obstructive subscale; the sexual domain can be parsed into the sexual bother score as distinct from the sexual function questions. Overall bowel bother can also be calculated with the UCLA-PCI bother item within EPIC-26. However, hormonal function versus bother distinction is not possible with EPIC-26 and the hormonal domain is limited to the hormonal summary score in EPIC-26.